

GEOFFREY M. COOPER

Education:

1969 B.S. Massachusetts Institute of Technology, Cambridge, MA (Biology)

1973 Ph.D. University of Miami, FL (Biochemistry)

Postdoctoral Training:

1973 - 1975 Fellow, McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI

Academic Appointments

1975 - 1978 Assistant Professor, Department of Pathology, Harvard Medical School at the Sidney Farber Cancer Institute, Boston, MA

1978 - 1984 Associate Professor, Department of Pathology, Harvard Medical School at the Dana-Farber Cancer Institute, Boston, MA

1984 – 1997 Professor of Pathology, Harvard Medical School at the Dana-Farber Cancer Institute, Boston, MA

1998 – present: Professor of Biology, Boston University, Boston, MA

1998- 2010 Chair, Department of Biology, Boston University, Boston, MA

1998- 2010 Associate Director, Bioinformatics Program, Boston University, Boston, MA

2010- 2015: Associate Dean of the Faculty, Natural Sciences, College of Arts and Sciences, Boston University, Boston, MA

Awards and Honors:

1967 National Science Foundation Undergraduate Research Fellowship

1971 Maytag Fellowship

1973 Jane Coffin Childs Postdoctoral Fellowship

1981 American Cancer Society Faculty Research Award

1984 Burroughs-Wellcome Visiting Professorship

1984 National Academy of Sciences U.S. Steel Award in Molecular Biology

Major Committee Assignments:

1981 – 1986 Leukemia Society of America, Medical and Scientific Advisory Committee

- 1986 – 1990 NIH Molecular Biology Study Section
- 1991 – 1997 NIH Reproductive Scientist Development Program, Evaluation Committee
- 1995 – 1997 External Advisory Committee, Columbia University Center for Reproductive Sciences
- 2000-2005 Scientific Advisory Council, Society for Women's Health Research
- 2000-2005 Biomedical Research Committee, The Medical Foundation, Boston, MA
- 2003-2005 Scientific Advisory Panel, The Iacocca Foundation
- 2006-2009 RAISE Advisory Board

Consulting:

- 1982 - 1990 New England Nuclear/DuPont Medical Products
- 1994 CLONTECH Laboratories
- 1993 - 1997 Sandoz Pharmaceutical Corporation

Teaching Experience:

- 1975-1981 Board of Tutors in Biochemical Sciences, Harvard University
- 1977-1983 Director of Tumor Virology Course, Department of Biochemistry, Harvard University and Department of Pathology, Harvard Medical School
- 1981 Course Instructor, Introduction of Macromolecules into Mammalian Cells, Cold Spring Harbor Laboratory, New York
- 1984-1997 Lecturer in Virology and Cell Biology courses, Harvard Medical School
- 1992-1995 Instructor, Animal Virology course, Harvard Medical School
- 1998– Cell Biology, BI203, Boston University
- 2006- Honors Cell Biology, BI213, Boston University

Editorial Boards:

- 1978 - 1988 Editorial Board, Journal of Virology
- 1985 - 1987 Associate Editor, Journal of Clinical Laboratory Analysis
- 1984 - 1990 Associate Editor, Cancer Research

Journal Articles (H index=60; 5 most significant papers highlighted in bold)

1. Cooper GM and Fox MS. 1969. Relationship between transformation frequency and gene function in the histidine degrading enzymes of *Bacillus subtilis*. *Biochem Biophys Res Commun.* 34:777-783.
2. Cooper GM and Greer S. 1970. Irreversible inhibition of dehalogenation of 5-iodouracil by 5-diazouracil and reversible inhibition by 5-cyanouracil. *Cancer Res.* 30:2937-2941.
3. Cooper GM, Dunning WF, and Greer S. 1972. Role of catabolism in pyrimidine utilization for nucleic acid synthesis in vivo. *Cancer Res.* 32:390-397.
4. Cooper GM and Greer S. 1973. The effect of inhibition of cytidine deaminase by tetrahydouridine on the utilization of deoxycytidine and 5-bromodeoxycytidine for deoxyribonucleic acid synthesis. *Mol. Pharmacol.* 9:698-703.
5. Cooper GM and Greer S. 1973. Phosphorylation of 5-halogenated deoxycytidine analogues by deoxycytidine kinase. *Mol. Pharmacol.* 9:704-710.
6. Cooper GM. 1973. Phosphorylation of 5-bromodeoxycytidine in cells infected with herpes simplex virus. *Proc Natl Acad Sci USA.* 70:3788-3792.
7. Cooper GM and Temin HM. 1974. Infectious Rous sarcoma virus and reticuloendotheliosis virus DNAs. *J. Virol.* 14:1132-1141.
8. Schildkraut I, Cooper GM, and Greer S. 1975. Selective inhibition of the replication of herpes simplex virus by 5-halogenated analogs of deoxycytidine. *Mol Pharmacol.* 11:153-158.
9. Cooper GM and Temin HM. 1975. Infectious DNA from cells infected with Rous sarcoma virus reticuloendotheliosis virus, or Rous-associated virus-O. *Cold Spring Harbor Sym Quan Biol.* 39:1027-1032.
10. Cooper GM and Temin HM. 1976. Lack of infectivity of the endogenous avian leukosis virus related genes in the DNA of uninfected chicken cells. *J Virol.* 17:422-433.
11. Cooper GM and Castellot SB. 1977. Assays of non-infectious fragments of DNA of avian leukosis virus-infected cells by marker rescue. *J Virol.* 22:300-307.
12. Cooper GM. 1978. Marker rescue of endogenous cellular genetic information related to the avian leukosis virus gene encoding RNA-directed DNA polymerase. *J Virol.* 25:788-796.
13. Neiman PE, McMillin-Helsel C and Cooper GM. 1978. Specific restriction of avian sarcoma viruses by a line of transformed lymphoid cells. *Virology* 89:360-372.
14. Cooper GM and Okenquist S. 1978. Mechanism of transfection of chicken embryo fibroblasts by DNA of Rous sarcoma virus. *J Virol.* 28:45-52.

15. Cooper GM and Silverman L. 1978. Linkage of the endogenous avian leukosis virus genome of virus-producing chicken cells to inhibitory cellular DNA sequences. *Cell* 15:573-577.
16. Copeland NG and Cooper GM. 1979. Transfection of exogenous and endogenous murine retrovirus DNAs. *Cell* 16:347-356.
17. Copeland NG, Zelenetz AD and Cooper GM. 1979. Transformation of NIH 3T3 mouse cells by DNA of Rous sarcoma virus. *Cell* 17:993-1002.
18. Cooper GM, Copeland NG, Zelenetz AD, and Krontiris TG. 1980. Transformation of NIH 3T3 mouse cells by avian retrovirus DNAs. *Cold Spring Harbor Symp Quan Biol*. 44:1169-1176.
19. Cooper GM, Okenquist S, and Silverman L. 1980. Transforming activity of DNA of chemically transformed and normal cells. *Nature* 284:418-421.
20. Copeland NG and Cooper GM. 1980. Transfection by DNAs of avian erythroblastosis virus and avian myelocytomatosis virus strain MC29. *J Virol*. 33:1199-1202.
21. Cooper GM and Neiman PE. 1980. Transforming genes of neoplasms induced by avian lymphoid leukosis virusus. *Nature* 287:656-659.
22. Copeland NG, Zelenetz AD, and Cooper GM. 1980. Transformation by subgenomic fragments of Rous sarcoma virus DNA. *Cell* 19:863-870.
23. Jenkins NA and Cooper GM. 1981. Integration, expression and infectivity of exogenously acquired proviruses of Rous-associated virus-O. *J Virol*. 36:684-691.
24. Copeland NG, Jenkins NA and Cooper GM. 1981. Integration of Rous sarcoma virus DNA during transfection. *Cell* 23:51-60.
- 25. Krontiris TG and Cooper GM. 1981. Transforming activity of human tumor DNAs. Proc Natl Acad Sci USA. 78:1181-1184.**
26. Shalloway D, Zelenetz AD and Cooper GM. 1981. Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus. *Cell* 24:531-541.
27. Lane MA, Sainten A and Cooper GM. 1981. Activation of related transforming genes in mouse and human mammary carcinomas. *Proc Natl Acad Sci USA* 78:5185-5189.
28. Cooper GM and Neiman PE. 1981. Two distinct candidate transforming genes of lymphoid leukosis virus-induced neoplasms. *Nature* 292:857-858.
29. Lane MA, Sainten A and Cooper GM. 1982. Stage-specific transforming gene or human and mouse B- and T-lymphocyte neoplasms. *Cell* 28:873-880.

30. Becker D, Lane MA and Cooper GM. 1982. Identification of an antigen associated with transforming genes of human and mouse mammary carcinomas. *Proc Natl Acad Sci USA* 79:3315-3319.
- 31. Der CJ, Krontiris TG, and Cooper GM. 1982. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. *Proc Natl Acad USA* 79:3637-3640.**
32. Cooper GM. 1982. Cellular transforming genes. *Science* 217:801-806.
33. Lane MA, Neary D, and Cooper GM. 1982. Activation of a cellular transforming gene in tumors induced by Abelson murine leukemia virus. *Nature* 300:569-661.
34. Der CJ and Cooper GM. 1983. Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas. *Cell* 32:201-208.
35. Goubin G, Goldman DS, Luce J, Neiman PE, and Cooper GM. 1983. Molecular cloning and nucleotide sequence of a transforming gene detected by transfection of chicken B-cell lymphoma DNA. *Nature* 302:114-119.
36. Diamond AM, Cooper GM, Ritz J, and Lane M.-A. 1983. Identification and molecular cloning of the human Blym transforming gene activated in Burkitt's lymphomas. *Nature* 305:112-116.
37. Morton CC, Taub R, Diamond A, Lane MA, Cooper GM, and Leder P. 1984. Mapping of the human Blym-1 transforming gene activated in Burkitt's lymphomas to chromosome 1. *Science* 223:173-175.
38. Feig L, Bast RC Jr, Knapp RC, and Cooper GM. 1984. Somatic activation of rasK in a human ovarian carcinoma. *Science* 223:698-701.
39. Lane M.-A., Sainten A, Doherty KM, and Cooper GM. 1984. Isolation and characterization of a stage specific transforming gene, Tlym-1, from T cell lymphomas. *Proc Natl Acad Sci.* 81:2227-2236.
40. Cooper GM, and Lane M.-A. 1984. Cellular transforming genes and oncogenesis. *Biochim Biophys Acta Reviews on Cancer* 738:9-20.
41. Finkel T and Cooper GM. 1984. Detection of a molecular complex between ras protein and transferrin receptor. *Cell* 36:1115-1121.
42. Finkel T, Der CJ, and Cooper GM. 1984. Activation of ras genes in human tumors does not affect localization, modification or nucleotide binding properties of p21. *Cell* 37:151-158.
43. Diamond A, Devine J, and Cooper GM. 1984. Nucleotide sequence of a human Blym transforming gene activated in a Burkitt's lymphoma. *Science* 225:516-519.

44. Becker D, Lane M.-A, and Cooper GM. 1984. Transformation of NIH 3T3 cells by DNA of the MCF-7 human mammary carcinoma cell line induces expression of an endogenous murine leukemia provirus. *Mol Cell Biol* 4:2247-2252.
45. Neiman P, Wolf C, Enrietto PJ, and Cooper GM. 1985. A retroviral myc gene induces pre-neoplastic transformation of lymphocytes in a bursal transplantation assay. *Proc Natl Acad Sci USA* 82:222-226.
46. Takahashi M, Ritz J, and Cooper GM. 1985. Activation of a novel human transforming gene (ret) by DNA rearrangement. *Cell* 42:581-588.
47. Der CJ, Finkel T, and Cooper GM. 1986. Biological and biochemical properties of human rasH genes mutated at codon 61. *Cell* 44:167-176.
48. Feig L, Pan B-T, Roberts TM, and Cooper GM. 1986. Isolation of ras GTP binding mutants using an *in situ* colony binding assay. *Proc. Natl. Acad. Sci. USA* 83:4607-4611.
49. Der CJ, Pan B-T, and Cooper, GM. 1986. RasH mutants deficient in GTP binding. *Mol. Cell. Biol.* 6:3291-3294.
50. Carney WP, Petit D, Hamer P, Der CJ, Finkel T, Cooper GM, LeFebvre M, Motaker H, Delellis R, Tischler AS, Dayal Y, Wolfe H, and Rabin H. 1986. A monoclonal antibody specific for an activated RAS protein. *Proc. Natl. Acad. Sci. USA* 83:7485-7489.
51. Feig LA, Corbley M, Pan BT, Roberts TM, and Cooper GM. 1987. Structure/function analysis of ras using random mutagenesis coupled with functional screening assays. *Mol Endocrinol* 1:127-136.
52. Stanton VP, and Cooper GM. 1987. Activation of human raf transforming genes by deletion of normal amino terminal coding sequences. *Mol. Cell. Biol.* 7:1171-1179.
53. Takahashi M, and Cooper GM. 1987. The ret transforming gene encodes a fusion protein homologous to tyrosine kinases. *Mol. Cell. Biol.* 7:1378-1385.
54. Goldman DS, Kiessling AA, Millette CF and Cooper GM. 1987. Expression of c-mos RNA in germ cells of male and female mice. *Proc. Natl. Acad. Sci. USA.* 84:4509-4513.
55. Eva A, Vecchio G, Diamond M, Tronick SR, Ron D, Cooper GM, and Aaronson SA. 1987. Independently activated dbl oncogenes exhibit similar yet distinct structural alterations. *Oncogene* 1:355-360.
56. Feig LA and Cooper GM. 1988. Relationship among guanine nucleotide exchange, GTP hydrolysis and transforming potential of mutated ras proteins. *Mol. Cell. Biol.* 8:2472-2478.
57. Goldman DS, Kiessling AA, and Cooper GM. 1988. Post-transcriptional processing suggests that c-mos functions as a maternal message in mouse eggs. *Oncogene* 3:159-162.

- 58 Feig LA and Cooper GM. 1988. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. *Mol Cell Biol* 8:3235-3243.
59. Herzog NK, Singh B, Elder J, Lipkin I, Trauger RJ, Millette CF, Goldman DS, Cooper GM and Arlinghaus RB. 1988. Identification of the protein product of the c-mos proto-oncogene in mouse testes. *Oncogene* 3:225-229.
60. Stanton VP, Nichols DW, Laudano AP and Cooper GM. 1989. Definition of raf amino terminal regulatory region by deletion mutagenesis. *Mol. Cell. Biol.* 9:639-647.
61. Wolfes H, Kogawa K, Millette CF and Cooper GM. 1989. Specific expression of nuclear proto-oncogenes before entry into meiotic prophase of spermatogenesis. *Science* 245:740-743.
62. O'Keefe SJ, Wolfes H, Kiessling AA and Cooper GM. 1989. Microinjection of antisense c-mos oligonucleotides prevents meiosis II in the maturing mouse egg. *Proc. Natl. Acad. Sci. U.S.A.* 86:7038-7042.
63. Pan BT, and Cooper GM. 1990. Role of phosphatidylinositol metabolism in ras-induced *Xenopus* oocyte maturation. *Mol. Cell. Biol.* 10:923-929.
64. Szeberenyi J, Cai H, and Cooper GM. 1990. Effect of a dominant inhibitory rasH mutation on neuronal differentiation of PC12 cells. *Mol. Cell. Biol.* 10:5324-5332.
65. Cai H, Szeberenyi J and Cooper GM. 1990. Effect of a dominant inhibitory rasH mutation on mitogenic signal transduction in NIH 3T3 cells. *Mol. Cell. Biol.* 10:5314-5323.
66. O'Keefe SJ, Kiessling AA and Cooper GM. 1991. c-mos is required for cyclin B accumulation during meiosis of mouse eggs. *Proc. Natl. Acad. Sci. USA*. 88:7869-7872.
67. Pal, S., Zinkel, S., Kiessling, A.A. and Cooper, G.M. 1991. c-mos expression in mouse oocytes is controlled by initiator-related sequences immediately downstream of the transcription initiation site. *Mol. Cell. Biol.* 11:5190-5196.
68. McGrew BR, Nichols DW, Stanton VP, Cai H, Whorf R, Patel V, Cooper GM and Laudano AP. 1992. Phosphorylation occurs in the amino terminus of the raf-1 protein. *Oncogene* 7:33-42.
69. Zinkel, S., Pal S., Szeberenyi, J., and Cooper, G.M. 1992. Identification of a negative regulatory sequence that inhibits c-mos transcription in somatic cells. *Mol. Cell. Biol.* 12:2029-2036.
70. Troppmair, J., Bruder, J.T., App, H., Cai, H., Liptak, L., Szeberenyi, J., Cooper, G.M., and Rapp, U.R. 1992. Ras controls coupling of growth factor receptors and protein kinase C in the membrane to Raf-1 and B-Raf protein serine kinases in the cytosol. *Oncogene* 7:1867-1873.

71. Szeberenyi, J., Erhardt, P., Cai, H., and Cooper, G.M. 1992. Role of Ras in signal transduction from the NGF receptor: relationship to protein kinase C, calcium, and cyclic AMP. *Oncogene* 7:2105-2113.
72. Cooper, G.M. 1992. Oncogenes as markers for early detection of cancer. *J. Cell. Biochem.* 16G:131-136.
73. Cai, H., Erhardt, P., Szeberenyi, J., Diaz-Meco, M.T., Johansen, T., Moscat, J., and Cooper, G.M. 1992. Hydrolysis of phosphatidylcholine is stimulated by Ras proteins during mitogenic signal transduction. *Mol. Cell. Biol.* 12:5329-5335.
74. Schweighoffer, F., Cai, H., Chevallier-Multon, M.C., Fath, I., Cooper, G., and Tocque, B. 1993. The *Saccharomyces cerevisiae* SDC25 C-domain gene product overcomes the dominant inhibitory activity of Ha-Ras Asn-17. *Mol. Cell. Biol.* 13:39-43.
75. Pal, S.K., Crowell, R., Kiessling, A.A., and Cooper, G.M. 1993. Expression of proto-oncogenes in mouse eggs and preimplantation embryos. *Mol. Repro. Dev.* 35:8-15.
76. Fanger, G.R., Erhardt, P., Cooper, G.M., and Maue, R.A. 1993. Ras-independent induction of rat brain type II sodium channel expression in nerve growth factor-treated PC12 cells. *J. Neurochem.* 61:1977-1980.
77. Cai, H., Erhardt, P., Troppmair, J., Diaz-Meco, M.T., Rapp, U.R., Moscat, J., and Cooper, G.M. 1993. Hydrolysis of phosphatidylcholine couples Ras to activation of the Raf protein kinase during mitogenic signal transduction. *Mol. Cell. Biol.* 13:7645-7651.
78. Pal, S.K., Torry, D.S., Serta, R., Crowell, R.C., Seibel, M.M., Cooper, G.M., and Kiessling, A.A. 1994. Expression and potential function of the c-mos proto-oncogene in human eggs. *Fertil. Steril.* 61:496-503.
79. Corbley, M.J., Cherington, V., Feig, L.A., Cooper, G.M., and Roberts, T.M. 1994. Rapid regeneration of virus from cells infected with a retroviral vector. *Biotechniques* 17:1102-1109.
80. Yamauchi, N., Kiessling, A.A., and Cooper, G.M. 1994. The Ras/Raf signaling pathway is required for progression of mouse embryos through the two-cell stage. *Mol. Cell. Biol.* 14:6655-6662.
81. Gebauer, F., Xu, W., Cooper, G.M., and Richter, J.D. 1994. Translational control by cytoplasmic polyadenylation of c-mos mRNA is necessary for oocyte maturation in the mouse. *EMBO J.* 13:5712-5720.
- 82. Yao, R., and Cooper, G.M. 1995. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. *Science* 267:2003-2006.**
83. Xu, W., and Cooper, G.M. 1995. Identification of a candidate c-mos repressor that restricts transcription of germ cell-specific genes. *Mol. Cell. Biol.* 15:5369-5375.

84. Erhardt, P., Troppmair, J., Rapp, U.R., and Cooper, G.M. 1995. Differential regulation of Raf-1 and B-Raf by cAMP. *Mol. Cell. Biol.* 15:5524-5530.
85. Yao, R., and Cooper, G.M. 1995. Regulation of the Ras signaling pathway by GTPase-activating protein in PC12 cells. *Oncogene* 11:1607-1614.
86. Yao, R., and Cooper, G.M. 1996. Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70S6K activity. *Oncogene* 13:343-351.
87. Erhardt, P., and Cooper, G.M. 1996. Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-xL. *J. Biol. Chem.* 271:17601-17604.
88. Cai, H., Wixler, V., Smole, U., Moscat, J., Rapp, U.R., and Cooper, G.M. 1997. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. *Mol. Cell. Biol.* 17:732-741.
- 89. Dudek,H., Datta, S.R., Franke, T.F., Birnbaum, M.J., Yao, R., Cooper, G.M., Segal, R.A., Kaplan, D.R., and Greenberg, M.E. 1997. Regulation of neuronal survival by the Ser/Thr protein kinase Akt. *Science* 275:661-665.**
90. Aktas, H., Cai, H., and Cooper, G.M. 1997. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. *Mol. Cell. Biol.* 17:3850-3857.
91. Lopes, U.G., Yao, R., and Cooper, G.M. 1997. p53-dependent induction of apoptosis by proteasome inhibitors. *J. Biol. Chem.* 272:12893-12896.
92. Erhardt, P., Tomaselli, K.J., and Cooper, G.M. 1997. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. *J. Biol. Chem.* 272:15049-15052.
93. Auer, K.L., Contessa, J., Brenz-Verca, S., Pirola, L., Rusconi, S., Cooper, G., Abo, A., Wymann, M.P., Davis, R.J., Birrer, M., and Dent, P. 1998. The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes. *Mol. Biol. Cell.* 9: 561-573.
94. Boglari, G., Erhardt, P., Cooper, G.M., and Szeberenyi, J. 1998. Intact Ras function is required for sustained activation and nuclear translocation of extracellular signal-regulated kinases in nerve growth factor-stimulated PC12 cells. *Eur. J. Cell Biol.* 75:54-58.
- 95. Pap, M., and Cooper, G.M. 1998. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. *J. Biol. Chem.* 273:19929-19932.**

96. Erhardt, P., Schremser, E.J., and Cooper, G.M. 1999. B-Raf inhibits programmed cell death downstream of cytochrome *c* release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 19:5308-5315.
97. Lin, H., Jurk, M., Gulick, T., and Cooper, G.M. 1999. Identification of COUP-TF as a transcriptional repressor of the *c-mos* proto-oncogene. J. Biol. Chem. 274:36796-36800.
98. Hartley, D. and Cooper, G.M. 2000. Direct binding and activation of STAT transcription factors by the herpesvirus saimiri protein Tip. J. Biol. Chem. 275:16925-16932.
99. Pap, M., and Cooper, G.M. 2002. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 β signaling pathway. Mol. Cell. Biol. 22:578-586.
100. Gross, V.S., and Cooper, G.M. 2002. Functional analysis of sperm from *c-mos*^{-/-} mice. Mol. Reprod. Dev. 62:519-524
101. Hartley, D. and Cooper, G.M. 2002. The role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J. Cell. Biochem. 85:304-314.
102. Pagon, Z., Volker, J., Cooper, G.M., and Hansen, U. 2003. Mammalian transcription factor LSF is a target of ERK signaling. J. Cell. Biochem. 89:733-746.
103. Zilz, A., and Cooper, G.M. 2004.. A binding site for germ cell nuclear factor within *c-mos* regulatory sequences. Mol. Reprod. Dev. 67:55-64.
104. Tullai, J.W., Schaffer, M.E., Mullenbrock, S., Kasif, S., and Cooper, G.M. 2004. Identification of transcription factor binding sites upstream of human genes regulated by the phosphatidylinositol 3-kinase and MEK/ERK signaling pathways. J. Biol. Chem. 279:20167-20177.
105. Gross, V.S., Hess, M., and Cooper, G.M. 2005. Mouse embryonic stem cells and preimplantation embryos require signaling through the phosphatidylinositol 3-kinase pathway to suppress apoptosis. Mol. Reprod. Dev. 70:324-332.
106. Adams, K.W., and Cooper, G.M. 2007. Rapid turnover of Mcl-1 couples translation to cell survival and apoptosis. J. Biol. Chem. 282:6192-6200.
107. Tullai, J.W., Chen, J., Schaffer, M.E., Kamenetsky, E., Kasif, S. and Cooper, G.M. 2007. GSK-3 β mediates repression of CREB target genes in quiescent cells. J. Biol. Chem. 282:9482-9491.
108. Tullai, J.W., Schaffer, M.E., Mullenbrock, S., Sholder, G., Kasif, S. and Cooper, G.M. 2007. Immediate-early and delayed primary response genes are distinct in function and genomic architecture. J Biol Chem. 282:23981-23995.

109. Terragni, J., Graham, J.R., Adams, K.W., Schaffer, M.E., Tullai, J.W. and Cooper, G.M. 2008. Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NF κ B transcription factors. *BMC Cell Biol.* 9:6.
110. Saxena, U.H., Powell, C.M.H., Fecko, J.K., Cacioppo, R., Chou, H.S., Cooper, G.M. and Hansen, U. 2009. Phosphorylation by cyclin C/cyclin-dependent kinase2 following mitogenic stimulation of murine fibroblasts inhibits transcriptional activity of LSF during G1 progression. *Mol. Cell. Biol.* 29:2335-2345.
111. Graham, J.R., Tullai, J.R. and Cooper, G.M. 2010. GSK-3 represses growth factor-inducible genes by inhibiting NF- κ B in quiescent cells. *J. Biol. Chem.* 285: 4472-4480.
112. Saxena, U.H., Owens, L., Graham, J.R. Cooper, G.M. and Hansen, U. 2010. Prolyl isomerase Pin1 regulates transcription factor LSF (TFCP2) by facilitating dephosphorylation at two serine-proline motifs. *J. Biol. Chem.* 285: 31139-31147.
113. Graham, J.R., Hendershott, M.C., Terragni, J. and Cooper, G.M. 2010. mRNA degradation plays a significant role in the program of gene expression regulated by phosphatidylinositol 3-kinase signaling. *Mol. Cell. Biol.* 30: 5295-5305.
114. Tullai, J.W., Tacheva, S., Owens, L.J., Graham, J.R. and Cooper, G.M. 2011. AP-1 is a component of the transcriptional network regulated by GSK-3 in quiescent cells. *PLoS ONE* 6:e20150.
115. Tullai, J.W., Graham, J.R. and Cooper, G.M. 2011. A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells. *Cell Cycle* 10: 3072-3077.
116. Terragni J., Nayak, G., Banerjee, S., Medrano, J.L., Graham, J.R., Brennan, J.F., Sepulveda, S. and Cooper, G.M. 2011. The E-Box binding factors Max/Mnt, MITF and USF1 Act coordinately with FoxO to regulate expression of Pro-apoptotic and cell cycle control genes by phosphatidylinositol 3-kinase/Akt/GSK3 signaling. *J. Biol. Chem.* 286: 36215-36227.
117. Mullenbrock S., Shah J. and Cooper, G.M. 2011. Global expression analysis identified a preferentially nerve growth factor-induced transcriptional program regulated by sustained mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) and AP-1 activation during PC12 differentiation. *J. Biol. Chem.* 286:45131-45145.
118. Nayak, G. and Cooper, G.M. 2012. p53 is a major component of the transcriptional and apoptotic program regulated by PI 3-kinase/Akt/GSK3 signaling. *Cell Death Dis.* 3:e400.
119. Tullai, J., Moss, M.E., Sepulveda, S.M., Brennan, J.F., Naya, F.J. and Cooper, G.M. 2013. Role of GSK-3 in CREB-mediated transcription regulation, hypertrophy and survival in cardiomyocytes. Manuscript submitted.

Book Chapters:

1. Cooper GM, Lane, Krontiris TG, Goubin G. Analysis of cellular transforming genes by transfection. In: Klein G, ed. *Advances in viral oncology*. New York: Raven Press, 1982.
2. Cooper GM. Transforming genes of chicken bursal lymphomas. In: Mak T, Bernstein A, eds. *Cellular and Molecular Biology of Hemopoietic Stem Cell Differentiation*. New York: Alan R. Liss, 1982.
3. Cooper GM, Lane MA. Tumor transforming genes. In: Rowley J., ed. *Chromosomes and Cancer From Molecules to Man*. New York: Academic Press, 1983.
4. Cooper GM. Transforming genes of human lung carcinomas. In: Mizell, M, ed. *Proc Intl. Lung Cancer Update Conf.*, Verlag Chemie Intl., 1983.
5. Cooper GM. Activation of Cellular Transforming Genes in Neoplasms. In: Bresciani, eds. *Hormones and Cancer 2, Proceedings of the Second International Congress*. New York:Raven Press, 1984.
6. Cooper GM. Transforming genes of chicken and human B cell lymphomas. In: Ginsberg HS and Vogel HJ, eds. *Transfer and expression of eucaryotic genes*. Academic Press, 1984.
7. Cooper GM. The 1984 Walter Hubert lecture: Activation of transforming genes in neoplasms. *Br. J. Cancer* 50:137-142.
8. Cooper GM. Molecular and functional analysis of ras and Blym Transforming Genes. In: Wahren eds. *Progress in cancer Research and Therapy Volume 32, Molecular Biology of Tumor Cells*, New York; Raven Press, 1985.
9. Cooper GM. Oncogenes in human neoplasms In: Cavalli F, Bonadonna G and Rozenzweig M, eds. *Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances*. Martinus Nijhoff Publishing, 1985.
10. Cooper GM. Transforming genes of human neoplasms. *Prog. Clin. Biol. Res.* 1986; 209:27-39.
11. Cooper GM. Oncogenes in human cancer. In: Hollmann KH, Verley JM, eds. *New Frontiers in Mammary Pathology*. Martinus Nijhoff, 1986.
12. Cooper GM, Goldman DS, Kiessling AA and Millette CF. The expression of oncogenes in germ cells. In: Haseltine FP and First NL, eds. *Progress in Clinical and Biological Research Volume 267, Meiotic Inhibition Molecular Control of Meiosis*. New York: Alan R. Liss, 1988.
13. Kiessling AA and Cooper GM. The expression of oncogenes in mammalian embryogenesis. In: Rosenblum IY and Heyner S, eds. *Regulation of Growth and Development*. CRC Press, 1989.

14. Cooper GM. Potential function of the mos protooncogene in germ Cell differentiation and early development. In: Bellve AR and Vogel HJ, eds. Molecular Mechanisms in Cellular Growth and Differentiation. Academic Press, 1991.
15. Cooper GM. Cellular function of proto-oncogenes. In: Haseltine FP and Findlay JK, eds. Growth Factors in Fertility Regulation. Cambridge University Press, 1991.
16. Cooper GM. Oncogenes and chemoprevention. In: Wattenberg L, Lipkin, M, Boone CW, and Kelloff, GJ, eds. Cancer Chemoprevention. CRC Press, 1992.
17. Cooper GM. 1994. Expression and function of c-mos in mammalian germ cells. *Adv. Devel. Biochem.* 3:127-148.
18. Cai, H., and Cooper, G.M. 1995. Inducible expression of the Ras (N-17) dominant inhibitory protein. *Met. Enzymol.* 255:230-237.

Books:

1. Cooper GM. 1990. Oncogenes. Jones and Bartlett Publishers, Boston.
2. Cooper GM. 1992. Elements of Human Cancer. Jones and Bartlett Publishers, Boston.
3. Cooper GM. 1995. Oncogenes 2d ed. Jones and Bartlett Publishers, Boston.
4. Cooper, G.M., Temin, R.G., and Sugden, B., eds. 1995. The DNA Proivirus: Howard Temin's Scientific Legacy. Amer. Soc. Microbiol., Washington.
5. Cooper, G.M. 1997. The Cell: A Molecular Approach. Amer. Soc. Microbiol., Washington and Sinauer Assoc., Sunderland, MA.
6. Cooper, G.M. 2000. The Cell: A Molecular Approach 2d ed. Amer. Soc. Microbiol., Washington and Sinauer Assoc., Sunderland, MA.
7. Cooper, G.M. and Hausman, R.E. 2003. The Cell: A Molecular Approach 3d ed. Amer. Soc. Microbiol., Washington and Sinauer Assoc., Sunderland, MA.
8. Cooper, G.M. and Hausman, R. E. 2006. The Cell: A Molecular Approach 4th ed. Amer. Soc. Microbiol., Washington and Sinauer Assoc., Sunderland, MA.
9. Cooper, G.M. and Hausman, R. E. 2009. The Cell: A Molecular Approach 5th ed. Amer. Soc. Microbiol., Washington and Sinauer Assoc., Sunderland, MA.
10. Cooper, G.M. and Hausman, R. E. 2013. The Cell: A Molecular Approach 6th ed. Sinauer Assoc., Sunderland, MA.

11. Cooper, G.M. and Hausman, R. E. 2015. *The Cell: A Molecular Approach* 7th ed. Sinauer Assoc., Sunderland, MA.